IDEXX LABORATORIES INC /DE — Director's Dealing 2020

May 12, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2020-05-11

Reporting Person: POLEWACZYK JAMES F (Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-11	Common Stock	M	1126	$62	Acquired	18898	Direct
2020-05-11	Common Stock	S	1126	$298.2848	Disposed	17772	Direct
2020-05-11	Common Stock	M	11110	$79.54	Acquired	28882	Direct
2020-05-11	Common Stock	S	11110	$298.7478	Disposed	17772	Direct
2020-05-11	Common Stock	M	4028	$64.24	Acquired	21800	Direct
2020-05-11	Common Stock	S	4028	$299.2946	Disposed	17772	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-11	Non-Qualified Stock Option (right-to-buy)	$62	M	1126	Disposed	2024-02-13	Common Stock (1126)	Direct
2020-05-11	Non-Qualified Stock Option (right-to-buy)	$79.54	M	11110	Disposed	2025-02-13	Common Stock (11110)	Direct
2020-05-11	Non-Qualified Stock Option (right-to-buy)	$64.24	M	4028	Disposed	2024-05-31	Common Stock (4028)	Direct

Footnotes

F1: Includes 23 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2020.

F2: Represents the weighted average price of the shares sold ranging from a low of $298.27 to a high of $298.323 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F3: Represents the weighted average price of the shares sold ranging from a low of $298.324 to a high of $299.25 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F4: Represents the weighted average price of the shares sold ranging from a low of $299.25 to a high of $299.42 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F5: Grant of option to buy 6,039 shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F6: Grant of option to buy 5,555 shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2016 without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F7: Grant of option to buy 10,071 shares of Issuer common stock that became exercisable in five annual installments beginning June 1, 2015 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F8: Not applicable.